INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 425m ago
HOUSE PTR24m ago
SEC 13F24m ago
ROBINHOOD CHAIN24m ago
Corporate insider
ML

Merendino Lauren

Chief Commercial OfficerCIK 0001855298

EDGAR filingsOpen in network
Disclosed transactions17
Buys / sells0 / 0
Max Insider Score9
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
40.6K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Day One Biopharmaceuticals, Inc.Chief Commercial Officer · Nov 7, 2025
9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D
—
69.4K sh
Apr 23, 2026
Apr 23, 2026
traded Apr 23, 2026
+0d
SEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
330.2K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
90.0K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
110.0K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
25.8K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
19.0K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
60.2K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
90.0K sh
Apr 23, 2026Apr 23, 2026
traded Apr 23, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
110.0K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
74.0K sh
Jan 30, 2026Jan 30, 2026
traded Jan 30, 2026
+0dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
90.0K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
90.0K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
90.0K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
90.0K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Grant or award
A—
330.2K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence

9
ML
Merendino LaurenChief Commercial Officer
DAWNDay One Biopharmaceuticals, Inc.
Disposition to issuer
D—
330.2K sh
Nov 6, 2025Nov 7, 2025
traded Nov 6, 2025
+1dSEC FORM 4

Evidence